Bluefield Innovations
A collaboration between a research university and a healthcare investment firm that provides funding, scientific review, and operational support to advance early-stage therapeutic research from concept through preclinical development and commercialization. The program was launched with up to $65 million in initial funding to support translational projects, IND-enabling studies, and formation or licensing of spin-out companies.
Industries
Nr. of Employees
small (1-50)
Bluefield Innovations
Baltimore, Maryland, United States, North America
Services
Provides funding to advance early-stage therapeutic research through preclinical milestones.
Joint steering committee-led review and selection of project proposals and advisory support during development.
Assistance with licensing, formation of spin-out companies, and coordination of follow-on capital when projects show commercial potential.
Provides funding to advance early-stage therapeutic research through preclinical milestones.
Joint steering committee-led review and selection of project proposals and advisory support during development.
Assistance with licensing, formation of spin-out companies, and coordination of follow-on capital when projects show commercial potential.
Expertise Areas
- Translational research and preclinical development
- IND-enabling studies and regulatory readiness
- Small-molecule drug discovery
- Project funding and translational financing
Key Technologies
- Small-molecule therapeutics
- Target validation and selection
- Preclinical proof-of-concept studies
- IND-enabling study methodologies
News & Updates
Launch announcement describing creation of the collaboration, funding commitment, joint steering committee governance, and goals to advance early-stage therapeutics.
Announcement of the program's first funded project to advance a target implicated in multiple cancers and description of support to identify a clinical lead and move toward human trials.
Acceptance and funding of the program's first translational project to advance a cancer-relevant target toward a clinical candidate.
Launch announcement describing creation of the collaboration, funding commitment, joint steering committee governance, and goals to advance early-stage therapeutics.
Announcement of the program's first funded project to advance a target implicated in multiple cancers and description of support to identify a clinical lead and move toward human trials.
Acceptance and funding of the program's first translational project to advance a cancer-relevant target toward a clinical candidate.